A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Tuberculosis, Pulmonary Clinical Trial

Official title:

A Randomized Multicenter Clinical Trial of a New Treatment for Primary Smear- Positive Pulmonary Tuberculosis With Interleukin-2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04766307
• Other study ID #: 2015ZX10003001-002
• Status: Recruiting
• Phase: Phase 4
• Start date: July 20, 2016
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2021
• Source: Beijing Chest Hospital
• Contact: Naihui Chu, PhD
• Email: dongchu1994[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.

Description:

1. Design:The study is a multi-center, randomized, controlled, open clinical trial. 2. Population:Initial smear positive pulmonary tuberculosis patients who fulfill the inclusion and exclusion criteria. 3. Investigational regimens: Experimental group regimen:2HRZE/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month） The control group regimen: 2HRZE/4HR Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily). 4. Primary and Secondary outcome measures: primary efficacy outcome measures:(a)Negative conversion rate of sputum bacteria. (b)Sputum smear conversion proportion at the treatment completion . secondary efficacy outcome measure:Recurrence rate after treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1100
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate).

2. Is aged 18-65 years.

3. Chest X-ray showed that there were active tuberculosis foci in the lungs with one of the following cases: (1) sputum specimens (or sputum and bronchial lavage fluid) were 2+ once or 1+ twice ; (2) sputum smear positive and sputum X-pert positive.

4. Newly diagnosed cases receiving anti-TB treatment for less than one month.

5. No other immune preparations (such as: thymosin,IFN-y,BCG-PSN,Mycobacterium vaccae,Utilins,lentinan )were used in the past 3 months.

6. the urine analysis of Women of childbearing age are negative and agree to use the efficient contraception during the study period.

Exclusion Criteria:

1. Has a known allergy to any drug of treatment regimens.

2. There are serious complications or impaired renal function (serum creatinine is 1.5 times higher than the normal limit) or impaired liver function (ALT or AST levels are 3 times higher than the normal limit); hemoglobin is less than 7.0g/dl. Platelets less than 50x109/L.

3. Complication with Diabetic.

4. The screening diagnosis was isoniazid resistance or rifampin resistance

5. There are serious cardiovascular diseases, such as heart failure, hypertension, arrhythmia or post myocardial infarction state.

6. Is known to be pregnant or breast-feeding.

7. Karnofsky score is less than 50%.

8. Is taking any clinical trial in the past 3 months.

9. Is critically ill, and in the judgment of the investigator, not fit for the study or unlikely to complete the full course of study.

10. HIV is positive or AIDS patients.

11. Has Non tuberculous mycobacterial lung disease.

12. Merge with extra pulmonary tuberculosis.

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Drug:
• Interleukin-2
Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.

Locations

Country	Name	City	State
China	the central hospital of Changsha	Changsha	Hunan
China	Dalian Tuberculosis Hospital	Dalian	Liaoning
China	the Second hospital of Fuyang	Fuyang	Anhui
China	Fuzhou Chest Hospital	Fuzhou	Fujian
China	Guiyang Public Health Treatment Center	Guiyang	Guizhou
China	The Infectious Hospital of Handan	Handan	Hebei
China	Jiamusi Insititute For Tuberculosis Control	Jiamusi	Heilongjiang
China	The Infectious Hospital of mudanjiang	Mudanjiang	Heilongjiang
China	Jiangxi Chest Hospital	Nanchang	Jiangxi
China	the people's hospital of Jiangsu province	Nanjing	Jiangsu
China	Qingdao Chest Hospital	Qingdao	Shandong
China	Shenzhen third people's Hospital	Shenzhen	Guangzhou
China	Hebei Chest Hospital	Shijiazhuang	Hebei
China	Taiyuan Fourth People's Hospital	Taiyuan	Shanxi
China	Xian Chest Hospital	Xi'an	Shanxi
China	Zhengzhou Sixth People's Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment.	A cure was defined as who was smear- or culture-negative in the last month of treatment and on at least one previous occasion. Treatment completion was defined as patients who completed treatment but who does not have a negative sputum smear or culture result in the last month of treatment and on at least one previous occasion. Treatment failure was defined as patients whose sputum smear or culture is positive at 5 months or later during treatment.	two-month course intensive phase treatment, followed by a four-month consolidation phase treatment.Some TB patients with cavity should receive 9 total months (7 months of continuation therapy after the initial 2-month intensive phase).